



## Company Overview

Heat Biologics is a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

## Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting

Jun 4 2021, 9:00 AM EDT

## Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

May 20 2021, 7:30 AM EDT

## Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit

May 19 2021, 7:30 AM EDT

## Stock Overview

Symbol	HTBX
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week	\$ - \$

## Investor Relations

[investorrelations@heatbio.com](mailto:investorrelations@heatbio.com)

## Management Team

### Jeffrey Wolf

Founder, Chairman and CEO

### George Peoples, M.D., FACS

Chief Medical Advisor

### Anthony Manning, Ph.D.

Chief Scientific Advisor

### Guillermo (Bill) Arana, MS

Executive Director, Clinical Development

### William L. Ostrander

Chief Financial Officer

### Gary Vinson

Vice President, Chemistry and Manufacturing Controls (CMC)

### Cheni Kwok, Ph.D., CLP

Senior Business Development Advisor

### Matthew M. Seavey, Ph.D.

Executive Director of Special Projects

## Heat Biologics, Inc.

627 Davis Drive  
Suite 400  
Morrisville, NC 27560

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.